Workflow
医疗产品销售及维护服务
icon
Search documents
营收降7%!新氧净亏3600万,线下医美飙涨426%
Jin Rong Jie· 2025-08-16 12:32
Core Insights - The company is undergoing a significant transformation, facing structural challenges in the traditional internet medical beauty platform, as evidenced by a 7% year-over-year decline in total revenue to 379 million yuan and a net loss of 36 million yuan compared to a profit of 18.9 million yuan in the same period last year [1][3]. Revenue Performance - Total revenue for the first half of the year was 676 million yuan, down 6.9% year-over-year, with net losses widening to 67.95 million yuan from just 60,000 yuan in the same period last year [3]. - Revenue from information and appointment services, the company's core business, fell by 35.6% to 135 million yuan from 210 million yuan year-over-year, highlighting intense competition in the online medical beauty information service market [4]. - Revenue from medical product sales and maintenance services decreased by 28.1% to 76 million yuan from 106 million yuan year-over-year, reflecting a significant drop in order volume for medical beauty products [4]. Business Segment Analysis - The total transaction volume facilitated by the platform was 304 million yuan, down from 428 million yuan in the same period last year, indicating challenges in the traditional business sector [4]. - The offline chain business has seen explosive growth, with medical treatment service revenue increasing by 426.1% to 144 million yuan, becoming the largest revenue source for the company [5]. - As of June 30, the company operated 29 light medical beauty chain stores in major cities, with 25 stores achieving positive monthly operational cash flow, indicating a promising profitability outlook [5]. Strategic Initiatives - The company plans to expand the number of medical beauty centers to 50 by the end of 2025, with a long-term goal of reaching 1,000 stores within 8 to 10 years, reflecting management's confidence in the offline business strategy [5]. - The company is innovating its operational model by reducing drug and device distribution costs through centralized procurement and self-built product lines, achieving store efficiency rates 3 to 5 times higher than similar institutions [6].